Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

Abstract

Background/Aims

Adalimumab dose escalation is one of the most important options in refractory Crohn's disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn's disease patients with loss of response to adalimumab, since there are few reports of adalimumab dose escalation, especially in East Asia.

Methods

The clinical response to adalimumab dose escalation in Crohn's disease patients with loss of response to adalimumab was evaluated retrospectively, using the Crohn's disease activity index score, serum C-reactive protein levels, and endoscopic analyses.

Results

Of the 203 Crohn's disease patients treated with anti-tumor necrosis factor, 14 refractory Crohn's disease patients with loss of response to adalimumab received adalimumab dose-escalation therapy. The C-reactive protein level was significantly reduced from the start to weeks 12 and 52 of adalimumab dose escalation in the whole group, although there were no significant reductions of Crohn's disease activity index scores. Both Crohn's disease activity index scores and C-reactive protein levels were significantly reduced from the start to weeks 12 and 52 of adalimumab dose escalation in patients without previous infliximab treatment, although C-reactive protein levels were positive in all cases with previous infliximab exposure at weeks 12 and 52. Endoscopic mucosal healing was achieved with adalimumab dose escalation in 2 cases without previous infliximab treatment.

Conclusions

Adalimumab dose-escalation therapy is effective in refractory Crohn's disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment.

Introduction

Crohn's disease (CD) is a chronic inflammatory bowel disease that is characterized by mucosal inflammation of the gastrointestinal tract with periods of relapse and remission. Obtaining long-term deep remission is essential to prevent irreversible gastrointestinal damage and disability [1, 2]. Inhibition of tumor necrosis factor (TNF)-α is very important for the control of inflammatory lesions in CD, and subcutaneous adalimumab (ADA) is one of the most important drugs approved for the treatment of CD [3]. ADA is effective for the induction and maintenance of clinical remission in patients with moderate-to-severe CD, particularly in cases naïve to anti-TNF treatment [4, 5, 6].

Although anti-TNF therapies are effective for the medical management of CD, a significant percentage of patients who initially respond to the anti-TNF induction regimen lose their response over time, so-called loss of response (LOR). The LOR rate is 13% per patient-year with infliximab (IFX) [7] and 20.3% per patient-year with ADA [8, 9]. Two-thirds of all CD patients will experience LOR to IFX or ADA [10]. The therapeutic options in cases of LOR to anti-TNF therapies are dose escalation (increase in dosage or in the frequency of treatment administration), switch to another anti-TNF treatment, addition of an immunosuppressant, or switch to another therapeutic class [11, 12].

Dose escalation of ADA is one of the most important options in refractory CD patients with LOR, and several studies have shown that it is an effective and well-tolerated therapeutic option in such cases [13, 14, 15, 16]. ADA dose escalation resulted in a clinical response in about 60–80% of the CD cases [13, 17], but more than half of such CD patients will eventually experience LOR to ADA dose escalation [15]. However, there are few reports of ADA dose escalation in refractory CD patients with LOR to ADA, compared with those of IFX dose escalation in CD, especially in the East Asian area. In Japan, there is also little evidence regarding the effectiveness of ADA dose escalation in CD cases with LOR to ADA in the real world, since ADA dose escalation was finally approved in 2016 for use in CD. Recently, a multicenter study has demonstrated the efficacy and safety of escalation to ADA 80 mg every other week in Japanese patients with CD who lost response to maintenance ADA 40 mg every other week [18]. In refractory CD patients with LOR to ADA, it is very important to accumulate the evidence for ADA dose escalation in the real-world setting of anti-TNF treatment.

Therefore, in this study, the clinical response to ADA dose escalation of CD patients with LOR to ADA was evaluated retrospectively, using the CD activity index (CDAI) score, serum C-reactive protein (CRP) levels, and endoscopic analyses in the real-world setting of anti-TNF treatment.

Patients and Methods

Between July 2016 and November 2017, active CD patients (CDAI ≥150 or abnormal serum CRP elevation) with LOR to ADA were given subcutaneous ADA with dose escalation at Nagoya City University Hospital, Aichi Medical University Hospital, Kasugai Municipal Hospital, Nagoya City West Medical Center, Japanese Red Cross Nagoya Daini Hospital, and Gifu Prefectural Tajimi Hospital after the patients' informed consent was obtained. Before the start of ADA dose escalation, bacterial infectious enteritis was ruled out by stool cultures. Clostridium difficile infection was ruled out by C. difficile toxin testing and stool cultures. Cytomegalovirus infection was ruled out by pathological analysis of lesions [3, 19].

Intravenous IFX injections of 5 mg/kg were given as maintenance therapy every 8 weeks, in accordance with the Japanese protocol [20]. If the CD patients showed LOR to 5 mg/kg of IFX, the dose was escalated to 10 mg/kg [21]. In addition, regarding the CD cases with LOR to IFX, intravenous IFX injections of 5 mg/kg in weight that can be given at a minimum of every 4 weeks, the so-called period-shortening administration, was approved in Japan 2017. Subcutaneous doses of 40 mg of ADA were given as maintenance therapy every other week, in accordance with the Japanese protocol [22]. If the CD patients showed LOR to 40 mg of ADA, the CD patients received 80 mg of ADA as dose escalation every other week, according to the Japanese protocol (Fig. 1).

Fig. 1.

Disposition and flow of patients. ADA, adalimumab; IFX, infliximab; eow, every other week.

LOR was defined as the conditions having 3 months or more followed by CDAI ≥ 150 or abnormal serum CRP elevation without any infection.

Symptoms and Laboratory Assessment

Disease activity before and after subcutaneous ADA dose-escalation therapy was measured using the CDAI score [3, 4]. Response was defined as a reduction of ≥70 points (70-point response) or ≥100 points (100-point response) from week 0 in the CDAI score, and remission was defined as a CDAI score < 150 points [3, 4, 23]. The CDAI score was evaluated before this treatment, at weeks 12 and 52 after ADA dose escalation in CD patients with LOR to ADA.

CRP was reported to correlate with disease activity [24]. Therefore, serum CRP levels (normal range ≤0.30 mg/dL) were evaluated before this treatment and after 12 and 52 weeks of ADA dose escalation in CD patients with LOR to ADA.

Endoscopic Assessment

Colonoscopy or double balloon endoscopy was performed before and after ADA dose escalation in some CD patients with LOR to ADA. Endoscopic assessment of the lesions was performed according to the CDEIS: nonactivity, CDEIS ≤3; mild active stage, 3 ≤ CDEIS < 9; moderate active stage, 9 ≤ CDEIS < 12; and severe active stage, CDEIS ≥12 [3, 25, 26].

Statistical Analyses

The differences in CDAI scores and serum CRP levels between before this treatment and at 12 weeks or before this treatment and at 52 weeks after ADA dose escalation were assessed using the Wilcoxon signed-rank test in each group. p values < 0.05 were considered significant.

Results

Patients' Characteristics

A total of 203 CD patients received anti-TNF treatment (Fig. 1), with 78 receiving ADA and 125 patients receiving IFX as first-line anti-TNF treatment. No one received IFX injections of period-shortening administration in the present CD cases. Finally, 14 refractory CD patients with LOR to ADA received the ADA dose-escalation therapy. Of these 14 cases, 9 had ADA dose escalation after first-line ADA administration, 3 patients had ADA dose escalation after first-line IFX, second-line IFX dose escalation, and third-line ADA administration, and the remaining 2 cases had ADA dose escalation after first-line IFX and second-line ADA administration. A total of 12 CD patients with ADA dose escalation were included in the final analysis, since 1 case transferred to a different hospital after 1 month of ADA dose escalation, and the remaining case had both CDAI < 150 and a normal serum CRP level when ADA dose escalation started.

The baseline characteristics of the 12 patients receiving subcutaneous ADA therapy are shown in Table 1. All patients received more than 3 months of ADA therapy. The male/female ratio was 7/5, and the median ages at diagnosis and at start of therapy were 27.7 years (range 17–49) and 38.3 years (range 18–68), respectively. Median disease duration was 9.2 years (range 1–19). The 12 cases were divided into 2 L1, 1 L2, and 9 L3 types, according to the Montreal classification for CD. Six cases had perianal disease, and 4 cases had previous surgical resection. Regarding concomitant medication, 4 patients received prednisolone, 9 received 5-aminosalicylates, 3 received immunosuppressants (azathioprine), 4 received granulocyte and monocyte adsorptive therapies, 7 received enteral nutrition, and none of them had received previous IFX or biologic drugs (Table 1). One patient had a peripheral nerve disorder after 4 months of ADA dose-escalation therapy that required termination of the therapy (Case 8, Table 2). Two cases had surgical resection within 1 year after ADA dose-escalation therapy, since the condition had worsened (Case 4 and Case 12, Table 2).

Table 1.

Patients' baseline characteristics (N = 12)

Sex, male/female	7/5
Medianage at diagnosis (range), years	27.7 (17–49)
Median age at start of the therapy (range), years	38.3 (18–68)
Median disease duration (range), years	9.2 (1–19)
Extent of disease
L1	2 (17)
L2	1 (8)
L3	9 (75)
Perianal disease	6 (50)
Previous surgical resection	4 (33)
Concomitant medication
Prednisolone	4
5-aminosalicylates	9
Immunosuppressants (AZA)	3
GMA	4
Enteral nutrition	7

Values are presented as n (%) or n; unless otherwise stated. AZA, azathioprine; GMA, absorptive granulocyte and monocyte apheresis; L1, ileum; L2, colon; L3, ileocolon.

Table 2.

Relationship between CDAI and CRP before and at week 12 after ADA dose escalation in CD patients with LOR to ADA

Case	Age, years	Sex	Anti-TNF treatments before ADA dose escalation	Duration of anti-TNF treatments before ADA dose escalation, months	Strictures	CDAIa, b			CRPc, d, e, f
						0 weeks	12 weeks	52 weeks	0 weeks	12 weeks	52 weeks
Case 1	32	M	ADA	7	–	mild	remission	remission	–	–	–
Case 2	18	F	ADA	4	–	mild	remission	remission	–	–	–
Case 3	27	M	ADA	16	–	remission	remission	remission	+	–	–
Case 4	20	M	ADA	3	–	mild	mild		+	+
Case 5	25	M	ADA	11	–	moderate	remission	remission	+	–	–
Case 6	41	M	ADA	33	–	moderate	moderate	mild	+	+	–
Case 7	52	F	ADA	3	+	mild	mild	mild	+	+	+
Case 8	32	M	ADA	22	+	moderate	remission		+	–
Case 9	69	F	IFX → ADA	53	–	mild	mild	moderate	+	+	+
Case 10	37	M	IFX → IFX dose escalation → ADA	149	–	remission	remission	remission	+	+	+
Case 11	47	F	IFX → IFX dose escalation → ADA	122	+	remission	remission	remission	+	+	+
Case 12	32	F	IFX → IFX dose	56	+	mild	remission		+	+

CDAI: remission: score >150; mild: 150 ≤ score >220; moderate: 220 ≤ score >450; severe: score ≥450. CRP: -: ≤0.30 mg/dL; +: >0.30 mg/dL.

^aCDAI before and at week 12 after ADA dose escalation, p < 0.05 in the group without previous IFX treatment.

^bCDAI before and at week 52 after ADA dose escalation, p < 0.05 in the group without previous IFX treatment.

^cCRP level before and at week 12 after ADA dose escalation, p < 0.05 in the whole group.

^dCRP level before and at week 52 after ADA dose escalation, p < 0.05 in the whole group.

^eCRP level before and at week 12 after ADA dose escalation, p < 0.05 in the group without previous IFX treatment.

^fCRP level before and at week 52 after ADA dose escalation, p < 0.05 in the group without previous IFX treatment.

CDAI Scores and CRP Levels at 12 Weeks

The mean CDAI score decreased from 194 ± 27 (average ± SE) at the start of subcutaneous ADA dose-escalation therapy to 143 ± 16 at week 12 in the 12 CD patients with LOR to ADA, but the difference was not significant (1 > 0.05; Table 2). Four (33%) and 4 (33%) CD cases achieved 70-point and 100-point responses, respectively, at week 12 after ADA dose-escalation therapy started. Eight (67%) patients showed clinical remission at week 12 after ADA dose-escalation therapy started.

In CD patients without previous IFX treatment, the mean CDAI score was significantly decreased from 226 ± 34 (average ± SE) at the start of subcutaneous ADA dose-escalation therapy to 144 ± 21 at week 12 in the 8 CD patients with LOR to ADA (p = 0.043; Table 2). Four (50%) and 4 (50%) CD cases achieved 70-point and 100-point responses, respectively, at week 12 after ADA therapy dose escalation started. Five (63%) patients showed clinical remission at week 12 after ADA dose-escalation therapy started.

In the CD patients with previous IFX exposure, the mean CDAI scores before and at week 12 of ADA dose escalation were 132 ± 19 and 140 ± 23, respectively, in the 4 CD patients with LOR to ADA (p > 0.05; Table 2). Two (50%) patients showed clinical remission at week 12 after ADA dose-escalation therapy started in the group with previous IFX exposure.

The mean CRP (normal range ≤0.30 mg/dL) decreased significantly from 1.62 ± 0.67 mg/dL (average ± SE) at the start of subcutaneous ADA dose-escalation therapy to 0.76 ± 0.30 mg/dL at week 12 in the 12 CD patients with LOR to ADA (p = 0.011, Table 2). In the CD patients without previous IFX treatment, the mean CRP decreased significantly from 1.23 ± 0.79 mg/dL at the start of subcutaneous ADA dose-escalation therapy to 0.51 ± 0.31 mg/dL at week 12 in the 8 CD patients LOR to ADA (p = 0.036, Table 2). In the CD patients with previous IFX exposure, the mean CRP decreased from 2.39 ± 1.29 mg/dL at the start of subcutaneous ADA dose-escalation therapy to 1.26 ± 0.65 mg/dL at week 12 in the 4 CD patients LOR to ADA, but there was no significant difference (p > 0.05, Table 2).

CDAI Scores and CRP Levels at 52 Weeks

Among the 12 CD patients with ADA dose escalation, CDAI scores and CRP levels were evaluated at week 52 in 9 cases (Table 2). The mean CDAI score decreased from 190 ± 34 (average ± SE) at the start of subcutaneous ADA dose-escalation therapy to 140 ± 24 at week 52 in the 9 CD patients with LOR to ADA, but the difference was not significant (p > 0.05; Table 2). Three (33%) and 2 (22%) CD cases achieved 70-point and 100-point responses, respectively, at week 52 after ADA dose-escalation therapy started. Six (67%) patients showed clinical remission at week 52 after ADA dose-escalation therapy started.

In CD patients without previous IFX treatment, the mean CDAI score was significantly decreased from 224 ± 45 (average ± SE) at the start of subcutaneous ADA dose-escalation therapy to 126 ± 21 at week 52 in the 6 CD patients with LOR to ADA (p = 0.028; Table 2). Three (50%) and 2 (33%) CD cases achieved 70-point and 100-point responses, respectively, at week 52 after ADA therapy dose escalation started. Four (67%) patients showed clinical remission at week 52 after ADA dose-escalation therapy started.

In the CD patients with previous IFX exposure, the mean CDAI scores before and at week 52 of ADA dose escalation were 122 ± 23 and 167 ± 65, respectively, in the 3 CD patients with LOR to ADA (p > 0.05; Table 2). Two (67%) patients showed clinical remission at week 52 after ADA dose-escalation therapy started in the group with previous IFX exposure.

The mean CRP (normal range ≤0.30 mg/dL) decreased significantly from 1.28 ± 0.70 mg/dL (average ± SE) at the start of subcutaneous ADA dose-escalation therapy to 0.32 ± 0.11 mg/dL at week 52 in the 9 CD patients with LOR to ADA (p = 0.029, Table 2). In the CD patients without previous IFX treatment, the mean CRP decreased significantly from 1.35 ± 1.07 mg/dL at the start of subcutaneous ADA dose-escalation therapy to 0.14 ± 0.06 mg/dL at week 52 in the 6 CD patients LOR to ADA (p = 0.028, Table 2). In the CD patients with previous IFX exposure, the mean CRP decreased from 1.13 ± 0.45 mg/dL at the start of subcutaneous ADA dose-escalation therapy to 0.68 ± 0.14 mg/dL at week 52 in the 3 CD patients LOR to ADA, but there was no significant difference (p > 0.05, Table 2).

CDEIS

Among the 12 CD patients with ADA dose escalation, 3 cases (Case 2, Case 5, and Case 9, Table 2) could be evaluated endoscopically before and after the ADA dose escalation. In Case 2, inflammatory lesions (CDEIS = 9) were detected before ADA dose escalation, and endoscopic mucosal healing was observed after the therapy. In Case 5, inflammatory lesions (CDEIS = 11) were detected before ADA dose escalation, and mucosal healing was observed endoscopically after the therapy (Fig. 2). In Case 9, inflammatory lesions (CDEIS = 11) were detected before ADA dose escalation, but the lesions were not improved by the therapy, which was switched to another therapeutic class (ustekinumab, anti-interleukin-12/23 p40 monoclonal antibody).

Fig. 2.

Longitudinal and serpiginous (snake-like) ulcers are seen endoscopically in the terminal ileum (a) and transverse colon (b) before ADA dose-escalation therapy, and the lesions show mucosal healing in the terminal ileum (c) and transverse colon (d) after ADA dose-escalation therapy.

Discussion

The results of the present study show that serum CRP levels were significantly reduced from the start to week 12 and week 52 of ADA dose-escalation therapy in all CD cases with LOR to ADA (Table 2). Sixty seven percent of the patients showed clinical remission at week 12 after ADA dose-escalation therapy started, suggesting the excellent effectiveness of induction in all CD patients with LOR to ADA, although there were no significant reductions of CDAI scores at week 12 and week 52 compared with those before ADA dose-escalation therapy. A clinical response was observed in 99/124 (79%) CD patients at 3 months and in 62/107 (61%) CD patients at 12 months [13] and another Japanese paper shows that a clinical response was observed in 25/28 (89%) CD patients at 8 weeks and in 18/28 (64%) CD patients at 12 months [18]. In the ADA dose-escalation sub-cohort (ADA 80 mg every other week), the clinical remission rate was 75% (6/8) 48 weeks after ADA dose escalation in Japanese CD patients [16]. ADA dose escalation is one of the most important therapeutic options in CD patients with LOR to ADA. On multivariate analysis, 40 mg every week rather than 80 mg every other week was significantly associated with a clinical response to ADA dose escalation at 12 months [13]. ADA dose escalation (40 mg weekly) was clinically beneficial for children with CD who experienced nonresponse or flare on every other week dosing [14]. Adjustment to weekly ADA dosing has been shown to be a benefit for adults with CD and ulcerative colitis who have lost response or who had an inadequate response to therapy [14, 17, 27]. In Japan, ADA dose escalation with 80 mg every other week is approved, but that of 40 mg every week is unfortunately not approved. In many Western and Asian countries, ADA dose escalation of 40 mg every week can be used in CD patients with LOR to ADA, and we are hoping for the approval of this ADA dose-escalation regimen in Japan.

In our present study, ADA dose escalation was more effective for CD patients without previous IFX treatment than for those with previous IFX exposure. The serum CRP levels were significantly reduced from the start to week 12 and week 52 of ADA dose-escalation therapy in the CD cases without previous IFX treatment, although the serum CRP levels have been positive before, at week 12 and at week 52 after ADA dose escalation in all cases with previous IFX exposure (Table 2). A significantly higher rate of clinical remission was achieved with ADA dose escalation (40 mg weekly) in IFX-naïve CD patients with LOR to ADA high-dose administration (20–40 mg every other week) than in those with LOR to ADA low-dose administration (10–20 mg every other week), while there were no significant differences between the high and low-dose groups in the IFX-experienced CD patients, suggesting that ADA dose escalation is more effective for IFX-naïve CD patients than for IFX-experienced ones [14]. However, previous anti-TNF exposure (IFX or certolizumab use) was not associated with the risk factors predicting response to ADA dose escalation or tertiary LOR after ADA dose escalation, although previous anti-TNF exposure and elevated CRP predicted earlier time to tertiary LOR to ADA dose escalation [15]. Regarding the predictive factors of response of ADA dose escalation, LOR that developed after ≥10 months and disease with strictures were significantly associated with a clinical response to ADA dose escalation at 3 months, suggesting that previous anti-TNF treatment (IFX or certolizumab use) was not associated with the clinical response to ADA dose escalation at 3 months on multivariate analysis [13]. On multivariate analysis, 40 mg every week rather than 80 mg every other week and a CRP level ≤5 mg/L at ADA dose escalation were significantly associated with clinical response to ADA dose escalation at 12 months, suggesting that previous anti-TNF treatment (IFX or certolizumab use) was not associated with the clinical response to ADA dose escalation at 12 months [13]. In Japan regarding the predictive factors, the rates of clinical remission in IFX-naïve patients were numerically higher compared to IFX-experienced patients, although prior use of IFX was not significant in the logistic regression analysis of clinical remission [18]. Further large-scale studies may be needed to clarify the comparison between CD patients with and without previous IFX exposure among CD patients with LOR to ADA from the perspective of the effectiveness of ADA dose escalation, since our study was small-scale one. In addition, further large-scale studies may be also needed to evaluate the clinical factors related to response of ADA dose escalation.

In the present study, endoscopic mucosal healing was seen after ADA dose escalation in CD patients with LOR to ADA. In 2 cases without previous IFX treatment, inflammatory lesions were seen before the ADA dose escalation, and endoscopic mucosal healing was observed after the therapy. However, lesions were not improved by the ADA dose escalation in one case with previous IFX treatment. To the best of our knowledge, there have been no reports of the evaluation of the endoscopic findings in ADA dose escalation of CD patients with LOR to ADA. Regarding normal ADA administration, mucosal healing is an increasingly important therapeutic goal in the treatment of patients with CD [26, 28, 29]. However, it is difficult to achieve endoscopic mucosal healing, as compared to clinical remission. Following induction therapy with ADA, CD patients who continue to receive ADA are more likely to achieve mucosal healing than those given placebo [26]. In the EXTEND Trial, 27 and 24% of the CD patients receiving ADA had mucosal healing at 12 and 52 weeks, respectively [26]. We consider that it is important to evaluate whether endoscopic mucosal healing is achieved from the perspective of deep remission in CD cases with ADA dose escalation.

Regarding to biologics switching of anti-TNF treatment, it is well-known that the serum trough level of IFX and ADA predicts clinical outcome, and that LOR is related to a decrease in serum trough concentration [20, 30]. We have also shown the importance of analysis of IFX trough level in the CD patients with the switch from ADA to IFX [22], although the trough concentration of ADA could not be evaluated in the present study from the viewpoint of the ADA dose escalation.

In conclusion, ADA dose-escalation therapy was effective in refractory CD patients with LOR to ADA, especially in cases without previous IFX treatment.

Statement of Ethics

This study was approved by the Institutional Review Board at each participating hospital and was in accordance with the guidelines of the International Conference on Harmonization and ethical principles originating in the Declaration of Helsinki. Informed consent was obtained from the patients..

Disclosure Statement

The authors have no conflicts of interest to declare.